Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01642186
Recruitment Status : Completed
First Posted : July 17, 2012
Last Update Posted : July 23, 2021
The Fibrolamellar Cancer Foundation
Dana-Farber Cancer Institute/Brigham and Women¹s Cancer Center and Massachusetts General Hospital Cancer Center
Johns Hopkins University
University of California, San Francisco
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : July 16, 2021
Actual Study Completion Date : July 16, 2021